FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2783-2785 December 28, 2006 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Geyer, C. E. PubMed Citation

Metastatic breast cancer is incurable, so most oncologists favor sequential chemotherapy with one agent at a time over concurrent therapy with multiple agents.¹ The use of single agents on a sequential basis can control the growth of metastases and improve the quality of life without a detrimental effect on survival. This conventional practice is about to change as a result of the development of new targeted agents for cancer.²

These targeted therapies — drugs that are specifically designed to block one or more critical pathways involved in cancer-cell growth and metastases — have led to major advances in the treatment . . . [Full Text of this Article]

Source Information

From the Vermont Cancer Center, University of Vermont College of Medicine, and Fletcher Allen Health Care — all in Burlington, VT.

This article has been cited by other articles:

• Greshock, J., Cheng, J., Rusnak, D., Martin, A. M., Wooster, R., Gilmer, T., Lee, K., Weber, B. L., Zaks, T. (2008). Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines. Molecular Cancer Therapeutics 7: 935-943 [Abstract] [Full Text]  
• Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. -J., Panel Members, (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144 [Abstract] [Full Text]